Merck Sharp & Dohme Llc

This study tested a new vaccine called V116 in 313 adults with HIV to see if it can safely protect them from pneumococcal disease (a serious lung infection). The vaccine aims to trigger a strong immune response against 21 types of the bacteria. Researchers compared it to existing…

This early-stage study tested a new vaccine called V330, designed to protect against norovirus—a highly contagious virus that causes vomiting and diarrhea. Researchers gave the vaccine or a placebo to 245 healthy adults split into younger (18-49) and older (60-79) groups. The mai…

This study tested a new vaccine called V114 to see if it could prevent ear infections caused by certain bacteria in babies. Over 7,000 healthy infants around 2 months old took part. Researchers compared how many babies got vaccine-type ear infections and monitored for serious sid…

This early-stage study tested the safety and tolerability of V118 Formulation C in 65 healthy adults. Researchers monitored side effects like injection-site reactions and general symptoms to see how well the vaccine was tolerated. The goal was to gather initial safety data to sup…

This study tested a new vaccine called V116 in 882 children and teenagers (ages 2–17) who have a higher risk of getting pneumococcal disease due to conditions like diabetes, heart disease, or lung disease. The goal was to see if V116 is as good as or better than the current vacci…

This study looked at whether giving the HPV vaccine and the Moderna COVID-19 vaccine at the same doctor's visit is safe and works well for children ages 9 to 11. About 165 boys and girls took part. Researchers compared kids who got both vaccines together to those who got them on …

This study tested a 9-valent HPV vaccine in 1990 healthy Chinese females aged 9 to 45. The goal was to see if the vaccine triggers a strong immune response and is safe. Results showed the vaccine works well across all age groups, helping protect against HPV infections that can ca…

This study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 participants in China. Unfortunate…

This study tested a new two-drug combination (MK-4280A) in 441 people with advanced colorectal cancer that had spread and no longer responded to standard treatments. The goal was to see if the new treatment helps people live longer compared to usual care. The approach uses immuno…

This early-phase study tested a new drug called MK-4464, given alone or with another drug (pembrolizumab), in 64 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and how the drug moves through the body. This is n…

This early-phase study tested a new drug called MK-4830, either alone or combined with other cancer treatments like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety and see if tumors shrank. This is not a cure, but aims to control the d…

This study tested a new drug called MK-0616 in 303 adults with a genetic condition that causes very high cholesterol (heterozygous familial hypercholesterolemia). Participants took either the drug or a placebo for 24 weeks to see if it safely lowered their LDL (bad) cholesterol. …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the drug combo or a placebo plus chemo. The main goal was to see if the p…

This study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) helps men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. Over 1,200 men participated. The study was stopped early, and …

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find a safe dose and see if the drug can shrink tumors. Participants had already tried other treatments without s…

This study tested the drug pembrolizumab (an immunotherapy) against a placebo in 959 people with liver cancer who had no signs of cancer after surgery or local ablation. The goal was to see if the drug could delay or prevent the cancer from coming back and help people live longer…

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after surgery to remove the kidney. Nearly 1,000 adults with intermediate-to-high risk of recurrence received either pembrolizumab or a placebo every three we…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab could better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination extended the time with…

This study tested the drug lenvatinib in 127 children, adolescents, and young adults whose solid tumors had come back or stopped responding to treatment. The goal was to see if the drug could shrink tumors and to check for side effects. Participants were grouped by tumor type, in…

This study tested whether adults with HIV-1 whose virus is already under control could safely switch from a daily pill to a once-weekly combination of two experimental drugs (islatravir and MK-8507). 161 participants took part. The main goal was to check for side effects and see …

This study tested a new drug that combines two immunotherapy agents (pembrolizumab and vibostolimab) with chemotherapy for people with advanced non-small cell lung cancer who haven't had treatment before. The goal was to see if this combination helps people live longer compared t…

This early-phase study tested a new drug called vibostolimab, either alone or combined with pembrolizumab (and sometimes chemotherapy), in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right…

This study tested whether adding the immunotherapy drug pembrolizumab to standard supportive care helps Asian patients with advanced liver cancer live longer. The trial enrolled 453 patients who had already received one prior treatment. Results showed that pembrolizumab extended …

This early-phase study tested an experimental drug (MK-1454) given as a shot into tumors, either alone or with the immunotherapy pembrolizumab, in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation helps people with high-risk, locally advanced cervical cancer live longer without their cancer growing. About 1,060 participants received either pembrolizumab or a placebo alongside t…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma who haven't had prior treatment. About 674 adults took part. The goal was to see if the combination helps stop cancer from growing longer and impro…

This study tested a drug called ertugliflozin in 166 teenagers (ages 10-17) with type 2 diabetes who were already taking metformin. The goal was to see if adding this drug could safely lower blood sugar levels more than a placebo. After 24 weeks, the drug helped reduce HbA1C, a k…

This study tested a new treatment approach for muscle-invasive bladder cancer. It compared a combination of two drugs (enfortumab vedotin and pembrolizumab) given before and after surgery to the standard chemotherapy before surgery. The goal was to see if the new combination help…

This large Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery could improve outcomes for people with stomach or gastroesophageal junction cancer. Over 1,000 participants were randomly assigned to r…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that cannot be removed by surgery. The trial included 131 Chinese participants who had not received prior treatment for their advanced disease. Res…

This study tested whether adding vibostolimab to pembrolizumab (Keytruda) helps people with advanced PD-L1 positive non-small cell lung cancer live longer or keep cancer from growing, compared to pembrolizumab alone. Over 1,200 participants received either the combination or the …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and trastuzumab could help people with advanced HER2-positive stomach or gastroesophageal junction cancer live longer without their disease getting worse. About 738 adults with previous…

This study tested several experimental drug combinations, given before surgery, for people with stage III melanoma that can be removed. The goal was to see if these combinations are safe and work better than current treatments. About 146 adults took part, receiving different comb…

This study tested new drug combinations, including pembrolizumab (an immunotherapy), for people with advanced esophageal cancer that had gotten worse after one prior treatment. About 90 participants received different experimental treatments to see if they were safe and could shr…

This study tested whether the immunotherapy drug pembrolizumab could help prevent lung cancer from coming back in people with early-stage non-small cell lung cancer (stages IB to IIIA) who had already had surgery and standard chemotherapy. About 1,177 participants received either…

This study tested whether adding experimental drugs (boserolimab, MK-4830, or MK-0482) to the immunotherapy pembrolizumab could shrink tumors or slow cancer growth in 128 adults with advanced non-small cell lung cancer (NSCLC) who had already received anti-PD-(L)1 therapy. The ma…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with advanced bile duct cancer live longer. It involved 158 Chinese adults whose cancer had spread or could not be removed by surgery. The main goal was to see if the combi…

This study tested a new drug combination (MK-4280A) in 163 people with either a type of skin cancer (cutaneous squamous cell carcinoma) or endometrial cancer. The goal was to see if the treatment could shrink or eliminate tumors. Participants received either the new combination o…

This study tested a new once-daily combination pill (doravirine/islatravir) in 599 adults newly diagnosed with HIV who had never taken HIV medication. The goal was to see if the new pill could control the virus as well as or better than a standard three-drug regimen. Results show…

This early-stage study tested a new drug called opevesostat (MK-5684) in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. All participants had …

This study tested the drug pembrolizumab (Keytruda) alone or with other medicines in 296 people with high-risk bladder cancer that did not get better after standard BCG therapy. Participants were not able or willing to have their bladder removed. The goal was to see if the treatm…

This study looked at two ways of giving the drug sotatercept to 164 adults with pulmonary arterial hypertension (PAH), a condition where lung blood vessels narrow, making it hard to breathe. Researchers compared a standard weight-based dose to a simpler weight-banded approach to …

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with Hodgkin lymphoma and other B-cell blood cancers. The goal was to see if the combo is safe and can shrink tumors. Participants received the drugs alone or together, and researchers moni…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with advanced HER2-negative stomach or gastroesophageal junction cancer live longer. About 1,579 adults with inoperable or metastatic cancer took part. The goal was to see …

This study tested whether adding an experimental drug (MK-4830 or MK-0482) to the standard immunotherapy pembrolizumab could shrink tumors or slow cancer growth in people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). 102 people who had not …

This study tested whether switching to a two-drug pill (doravirine/islatravir) works as well as staying on a three-drug pill (BIC/FTC/TAF) for people whose HIV is already suppressed. About 643 adults with HIV took part. The main goal was to see if the new pill kept virus levels l…

This study tested whether adding lenvatinib to pembrolizumab helps people with advanced head and neck cancer that has come back or spread. About 511 adults with a specific type of head and neck cancer took part. The goal was to see if the combination shrinks tumors, delays cancer…

This study tested a new medicine called efinopegdutide in 381 adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to cirrhosis. The main goal was to see if the drug could reverse signs of liver inflammation without making scarring worse. R…

This study tested experimental treatments for melanoma that has spread to the brain. It involved 56 adults with stage IV melanoma and brain metastases who were not on steroids. The goal was to see if adding new drugs to pembrolizumab (an immunotherapy) is safe and works better th…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with pembrolizumab, in 182 adults with advanced solid tumors (including lung and triple-negative breast cancers). The main goal was to check safety and how the drug moves through the b…

This study tested a new medicine called MK-0616 in about 2,900 adults with high cholesterol. The goal was to see if it could safely lower bad (LDL) cholesterol more than a placebo. Participants took the drug or a dummy pill for 24 weeks, and researchers measured cholesterol chang…

This study tested a new drug combination (MK-7684A) in 192 people with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The goal was to see if the drug is safe and can shrink tumors or control the disease. Participants …

This study tested a new drug (MK-1454) injected directly into tumors, combined with the immunotherapy pembrolizumab, for people with advanced head and neck cancer that cannot be removed by surgery. The goal was to see if the combination worked better than pembrolizumab alone. The…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers that had stopped responding to standard treatments. The cancers included triple-negative breast, ovarian, gastric, colorectal, glioblastoma, biliary tract, and pancreat…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, against standard chemotherapy for women with advanced or recurrent endometrial cancer. The goal was to see if the combo could help people live longer without their cancer growing. The study involved 842 p…

This study looked at whether switching to a new once-daily pill (doravirine/islatravir) is safe and effective for people with HIV whose virus is already suppressed by their current medication. Over 600 adults took part. The main goal was to see if the new pill kept the virus unde…

This study tested whether adding a fourth drug, lenvatinib, to a standard three-drug regimen (chemotherapy plus pembrolizumab) could help people with advanced non-squamous lung cancer live longer or keep their cancer from growing. About 761 adults with metastatic disease that had…

This study tested whether adding two drugs—pembrolizumab (an immunotherapy) and olaparib (a targeted therapy)—to standard chemotherapy could help women with advanced ovarian cancer live longer without their cancer growing. Over 1,300 women with a type of ovarian cancer that does …

This study tested two drugs—pembrolizumab and brentuximab vedotin—in 304 people whose Hodgkin lymphoma had returned or not responded to prior therapy. The goal was to see which drug better delays cancer growth and extends life. Participants received treatment for up to 35 cycles …

This early-stage study tested the safety and how the body processes the antibiotic ceftolozane/tazobactam in 41 children with pneumonia caught in the hospital. The goal was to see if the drug is safe and to understand the right dose for this age group. Results will help design la…

This study tested whether adding lenvatinib to the immunotherapy drug pembrolizumab helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. Over 600 adults with tumors showing at least 1% PD-L1 took part. The goal was to see if the combinat…

This study tested a new drug called enlicitide (MK-0616) to see if it lowers 'bad' cholesterol better than current medications like ezetimibe and bempedoic acid. About 300 adults with high cholesterol and heart disease risk took part. The goal was to measure cholesterol reduction…

This study tested whether adding lenvatinib to pembrolizumab (immunotherapy) helps people with advanced bladder cancer who cannot receive standard platinum chemotherapy. About 505 participants received either the combination or pembrolizumab alone. The study was stopped early bas…

This study tested whether a combination of two drugs (pembrolizumab and lenvatinib) works better than standard chemotherapy for women with advanced or recurrent endometrial cancer. About 130 women with stage III, IV, or recurrent disease took part. The goal was to see if the comb…

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent high-risk skin cancer from returning after surgery and radiation. About 450 adults with advanced squamous cell skin cancer took part. The results suggest that adding pembrolizumab after s…

This study tested a new two-drug combination (MK-4280A) against standard chemotherapy in 203 people with classical Hodgkin lymphoma that had returned or stopped responding to prior treatments, including PD-(L)1 therapy. The goal was to see if the combination could help people liv…

This study looked at 462 people with advanced triple-negative breast cancer that had not spread before. After initial chemotherapy, some received a combination of olaparib and pembrolizumab, while others got more chemo plus pembrolizumab. The goal was to see if the new combo help…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 160 people with a rare type of advanced kidney cancer (non-clear cell renal cell carcinoma) that had not been treated before. The goal was to see if the drugs could shrink tumors. The treatment helped …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with triple-negative breast cancer (TNBC). Over 1,100 participants received either pembrolizumab plus chemo or a placebo plus chemo before surgery, then continued pembroliz…

This study tested an experimental drug called MK-2060 in 506 adults with end-stage kidney disease who need regular dialysis through a special tube (graft) in their arm. The goal was to see if the drug could prevent dangerous blood clots from blocking the graft. Participants recei…

This study tested a new treatment plan for people with advanced non-squamous lung cancer that has spread. Over 1,000 participants received either a combination of pembrolizumab (immunotherapy) and olaparib (targeted therapy) or pembrolizumab with pemetrexed (chemotherapy) after i…

This study tested whether adding two targeted drugs (lenvatinib and pembrolizumab) to standard chemotherapy helps people with advanced stomach or esophageal cancer live longer. About 895 adults with untreated, advanced cancer took part. The goal was to see if the new combination …

This early-stage study tested a new drug called MK-5684 in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goal was to check the drug's safety and how the body processes it, not to prove it works. Participants t…

This early-phase study tested the safety and tolerability of a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The goal was to see how the body handles the drug and if it can help control the disease. Because pati…

This study tested a drug called sotatercept (MK-7962) added to standard therapy for 46 Japanese adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe and move. The main goal was to see if the drug improves b…

This study tested whether adding lenvatinib to pembrolizumab helps people with advanced head and neck cancer that has come back or spread. 112 adults with a specific marker (PD-L1 positive) received either the drug combo or pembrolizumab alone. The goal was to see if the combinat…

This early-phase study tested a new drug called MK-4700, given alone or with another cancer drug (pembrolizumab), in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to check safety and find a dose that people can tolerate. No…

This study tested the drug pembrolizumab (Keytruda) given every 6 weeks instead of every 3 weeks in 66 people whose Hodgkin's lymphoma or PMBCL had come back or not responded to prior treatment. The main goal was to see how many patients had their tumors shrink or disappear. The …

This study tested whether adding an experimental drug (MK-4830) to standard chemotherapy and immunotherapy (pembrolizumab) could better reduce tumor DNA in the blood of people with advanced ovarian cancer. 160 participants with stage III or IV high-grade serous ovarian cancer wer…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in people with advanced colorectal cancer that had spread and stopped responding to earlier treatments. The goal was to see if this new combination helped people live longer compared to standard treatment…

This study tested a drug called vericiguat in over 6,000 adults with chronic heart failure and a weak heart pump. The goal was to see if it could lower the chance of dying from heart problems or being hospitalized for heart failure. Participants took the drug or a placebo along w…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation could help people with advanced head and neck cancer live longer without their disease getting worse. About 800 participants were randomly assigned to receive either pembrolizumab plu…

This study tested whether adding a maintenance drug called olaparib to standard treatment (pembrolizumab plus chemotherapy) helps people with advanced squamous non-small cell lung cancer live longer or keep the disease from growing. About 850 participants who had not received pri…

This study tested whether adding pembrolizumab (an immunotherapy) to lenvatinib (a targeted therapy) helps people with advanced liver cancer live longer or slow tumor growth compared to lenvatinib alone. About 794 adults with liver cancer that could not be treated with surgery or…

This study tested a new drug combination (MK-4280A) in Chinese adults with advanced colorectal cancer that had spread and was no longer responding to standard treatments. The goal was to see if the new combo helps people live longer compared to usual care. About 94 participants t…

This study tested a combination of two drugs (pembrolizumab and axitinib) against the standard single drug (sunitinib) in 861 people with advanced kidney cancer that had spread. The goal was to see if the combo could help people live longer and keep the cancer from growing. Resul…

This study tested a new antibiotic called MK-7655A in 115 children from birth to 18 years old who had serious bacterial infections. The goal was to see if the drug is safe and works better than standard treatments. Children were given the drug or a control treatment, and research…

This study tested a drug called vorinostat in 56 people with follicular lymphoma or other slow-growing B-cell lymphomas that had returned or stopped responding to prior treatments. The main goal was to see if the drug could shrink tumors and to check its safety. The study was com…

This study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer procedure called TACE helps people with liver cancer that cannot be cured. About 479 adults with liver cancer that had not spread outside the liver took part. The goal was to see …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with stomach or gastroesophageal junction cancer. About 120 adults in China received either the drug combo or a placebo plus chemo before and after surgery. The goal was to…

This study tested whether adding lenvatinib to standard chemotherapy plus pembrolizumab helps adults from mainland China with advanced nonsquamous non-small cell lung cancer live longer or slow tumor growth. About 200 participants received either the four-drug combo or a placebo …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps women with advanced cervical cancer live longer. Over 600 women whose cancer had spread or returned took part. The results showed that the combination improved survival, especiall…

This study tested a new combination of two drugs (lenvatinib and pembrolizumab) for people with head and neck cancer that returned or spread and stopped responding to standard chemotherapy and immunotherapy. About 408 adults took part. The main goal was to see if the combination …

This study tested a new vaccine called V116 in over 1,400 adults aged 50 and older to see if it could prevent pneumococcal disease, which can cause pneumonia and other serious infections. The vaccine was compared to the current standard vaccine (PPSV23). Researchers checked how w…

This large study tested a single dose of clesrovimab in over 3,600 healthy preterm and full-term infants to see if it could prevent serious RSV lung infections. The medicine was given before or during RSV season and compared to a placebo. Results showed fewer babies getting sick …

This study tested a new once-monthly pill, MK-8527, to see if it is safe and how it works in people at low risk for HIV. 352 adults took either the pill or a placebo. The main goal was to check for side effects and how the drug moves through the body.

This study tested a new pneumococcal vaccine (V116) given at the same time as the seasonal flu shot in 1,080 adults aged 50 and older. The goal was to see if giving both vaccines together is safe and produces a strong immune response. Participants received either V116 with the fl…

This study tested a new medicine called clesrovimab in over 1,000 infants and children at high risk for severe RSV infection. The goal was to see if it is safe and works as well as an existing treatment, palivizumab. Participants received either the new drug or the standard one, …

This study tested a new pneumococcal vaccine (V116) in 518 adults aged 18-64 who are at higher risk for pneumococcal disease due to conditions like diabetes or chronic lung disease. The goal was to see if V116 is safe and triggers a strong immune response compared to existing vac…

This study tested whether a higher-than-normal dose of MK-8527, a once-monthly pill to prevent HIV, affects heart rhythm. 42 healthy adults took the study drug, a placebo, or an active control. The main goal was to measure changes in the QT interval, a key heart rhythm marker. Th…

This study tested a new drug called MK-8189 (elpipodect) in 224 adults experiencing an acute episode of schizophrenia. Participants received either MK-8189, a placebo, or an active control drug (risperidone) for 4 weeks. The main goal was to see if MK-8189 reduces schizophrenia s…

This early-stage study tested a new drug called MK-8189 (elpipodect) in 53 adults with schizophrenia or schizoaffective disorder. The main goal was to see if the drug is safe and tolerable when given in increasing doses. Participants were stable on their current treatment and in …

This study tested a new drug called MK-8189 (elpipodect) in 499 adults having an acute episode of schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo. Participants took different doses of the drug or a placebo for 6 we…

This early-stage study tested a new drug called MK-1167 in 28 people with Alzheimer's disease who were already taking donepezil. The main goal was to see if MK-1167 is safe and how the body processes it. Researchers measured side effects and drug levels in the blood. This is a fi…

This early-stage study tested the safety of a new drug called MK-8189 (elpipodect) in 34 adults with stable bipolar I disorder. Participants took multiple doses of the drug, and researchers monitored for side effects. The study did not test whether the drug works; it only looked …

This early-phase study tested the safety and tolerability of a new drug called MK-8189 (elpipodect) in 63 adults with schizophrenia, including both younger and elderly participants. The goal was to find safe dosing schedules and see how the drug moves through the body. No claims …

This early-stage study tested a new drug called MK-8189 (elpipodect) in 29 people with Alzheimer's disease, some of whom also had symptoms like agitation or psychosis. The main goal was to see if the drug is safe and tolerable at different doses. Researchers tracked side effects …

This study looked at how a drug called MK-5475 moves through and leaves the body. Eight healthy men received a single dose with a radioactive tag so researchers could measure it in blood, urine, and stool. The goal was simply to learn how the drug is broken down and eliminated, n…

This study checked whether a high dose of the experimental drug MK-8189 (elpipodect) causes heart rhythm changes in people with schizophrenia. 107 participants received the drug, a placebo, and an active control in a crossover design. The main goal was to see if the drug's effect…

This study looked at how the body handles MK-4482, an experimental drug, in 16 healthy Chinese men. Participants took single and multiple doses to measure drug levels and check for side effects. The goal was to gather safety and processing data, not to treat any disease.

This study looked at how the drug bomedemstat (MK-3543) moves through the body in people with mild or moderate liver problems compared to healthy volunteers. Nine participants received a single dose, and researchers measured drug levels in the blood. The goal was to understand if…

This study looked at how the body processes efinopegdutide, a potential drug for fatty liver disease, in people with moderate to severe liver damage compared to healthy people. A total of 22 adults received a single dose, and researchers measured drug levels and safety. The goal …

This study looked at how the experimental prostate cancer drug opevesostat (MK-5684) moves through the body in men with moderate liver impairment compared to healthy men. Sixteen male participants received a single dose, and researchers measured drug levels over time. The goal wa…

This study tested whether the experimental HIV drug ulonivirine (MK-8507) causes changes in heart rhythm. 62 healthy adults received the drug or a placebo, and their heart activity was measured. The goal was to gather safety information, not to treat any disease.

This study looked at how the drug MK-5684 stays in the body of men with severe kidney failure or end-stage kidney disease compared to healthy men. Researchers measured drug levels in the blood over time. The goal was to understand how kidney problems affect the drug, not to treat…

This completed phase 1 study looked at how elpipodect is absorbed, broken down, and removed from the body in 6 healthy adults. Participants gave blood, urine, and stool samples to measure the drug and its byproducts. The goal was purely to understand the drug's behavior, not to t…

This study looked at how the drug MK-8527 moves through the body in people with mild or moderate liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood over time to understand how liver function affects the drug. The study involved 18 adult…

This study looked at how the body processes a drug called MK-1084 when taken alone or with two other common drugs (itraconazole and phenytoin). It involved 28 healthy adults and measured drug levels in the blood over time. The goal was purely to gather information, not to treat a…

This study looked at how two HIV medications, doravirine and islatravir, move into breast milk in 12 healthy breastfeeding women. Participants took a single dose and provided milk and blood samples over 24 hours. The goal was to estimate how much drug a nursing infant might recei…

This study looked at how drinking coffee or tea at the same time as a new drug called enlicitide changes the amount of drug in the blood. Sixty healthy adults took enlicitide with coffee, tea, or water, and researchers measured drug levels over time. The goal is to see if coffee …

This study looked at how a new drug called MK-1084 changes the way the body processes two common medicines: rosuvastatin (for cholesterol) and metformin (for diabetes). Sixteen healthy adults took part, and researchers measured medicine levels in their blood over time. The goal w…

This study looked at how a drug called MK-8527 moves into breast milk after a single dose. 13 healthy women who were at least 6 weeks postpartum took part. Researchers measured the amount of drug in breast milk over 120 hours to understand how much a baby might receive. The goal …

This early-stage study tested the safety and tolerability of a new drug called MK-1167 in 30 healthy adults. Researchers monitored for side effects and how well participants tolerated the drug. The goal was to gather safety information, not to treat any disease.

This early-stage study tested a single dose of an experimental drug called MK-2060 in 14 people with advanced chronic kidney disease. The main goal was to check for side effects, especially bleeding, and to measure how the drug moves through the body. Only the first part of the s…

This study looked at how a tuberculosis drug called rifabutin changes the amount of a new HIV medicine, MK-4646, in the blood. 18 healthy adults took MK-4646 alone and then with rifabutin to compare drug levels and safety. The results will help doctors decide the right dose when …

This study looked at how taking MK-1084 with food, in different pill forms, or with a common heartburn drug changes its levels in the blood. 56 healthy adults each received a single dose of MK-1084 under various conditions. The results will help guide how the drug should be taken…

This study looked at how two different forms of the drug sotatercept behave in the bodies of 146 healthy women who cannot become pregnant. One form is a liquid given through an autoinjector pen, and the other is a powder that must be mixed before injection. The goal was simply to…

This study in 52 healthy adults compares two different tablet forms of the experimental drug calderasib and checks whether food changes how the drug is absorbed. Participants take a single dose and provide blood samples over time. The goal is to understand the drug's behavior in …

This study looked at how the body absorbs, breaks down, and gets rid of a drug called ulonivirine. Eight healthy adults took a single dose with a radioactive marker so scientists could track it in blood, urine, and stool. The goal was purely to learn about the drug's path, not to…

This early-stage study tested the safety and how the body processes the experimental drug MK-8189. It included 55 people: some with schizophrenia (taking the drug alone or with their usual medication) and some healthy volunteers. The main goal was to find a dose that is safe and …

This study looked at how belzutifan changes the amount of metformin in the blood and urine of 14 healthy adults. Participants took metformin alone, then metformin with belzutifan, and researchers measured drug levels. The goal was to understand the interaction, not to treat any d…

This study looked at how the drug calderasib is absorbed, spread, broken down, and removed from the body in 8 healthy adults. Participants took a single dose with a radioactive tracer so scientists could measure the drug in blood, urine, and stool. The goal was purely to understa…

This study looked at how the drug MK-8189 (elpipodect) behaves in people with mild or moderate liver problems compared to healthy people. Researchers measured drug levels in the blood and checked for side effects. The goal was to understand if liver impairment changes how the bod…

This study looked at how the drug MK-8527 behaves in people with moderate or severe kidney impairment compared to healthy volunteers. 18 participants received a single dose, and researchers measured drug levels in the blood over time. The goal was to understand how kidney functio…

This study looked at how a new cancer drug, MK-1084, affects the levels of two other drugs (midazolam and digoxin) in the body. 28 healthy adults took these drugs with and without MK-1084 to see if there were any changes. The goal was to understand potential drug interactions, no…

This study looked at how the drug MK-1084 (calderasib) moves through the body in people with moderate or severe kidney problems compared to healthy people. Researchers measured drug levels in the blood over time and checked for side effects. The goal was to understand if kidney f…